Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

A correction has been published 1

Original ArticleFree PreviewArchive

Lente Insulin in the Treatment of Diabetes

List of authors.
  • Robert E. Slayton, M.D.†,
  • Ruth E. Burrows, M.D.‡,
  • and Alexander Marble, M.D.§

HAVING been employed in certain other countries for over two years previously, lente insulin was made available for general use in the United States in August, 1954. One of the first papers describing the results of clinical trials of insulin zinc suspensions came from their originators, Hallas-Møller et al.1 and was published late in 1952. Not long afterward, Lawrence and Oakley,2 of London, reported their experience in the early use of the new preparations. Since then numerous articles have appeared, chiefly in European journals.3 4 5 6 7 8 9 10 We have had the opportunity of using lente insulin since the summer of 1953, first as . . .

Funding and Disclosures

* Presented in part at the First Interstate Scientific Assembly, Washington, D. C., November 1, 1954.

From the Elliott P. Joslin Camp, Charlton, Massachusetts, and the Joslin Clinic and the Baker Clinic Research Laboratory, New England Deaconess Hospital, Boston.

Technical assistance was given by the following medical students: Sidney I. Le Bauer (Duke), Edward J. G. Noble (Toronto) and Richard V. Paul (Tufts).

¶ Kindly supplied by Eli Lilly and Company, Indianapolis, Indiana.

Author Affiliations

CHARLTON AND BOSTON, MASSACHUSETTS

† Formerly, resident in medicine, New England Deaconess Hospital. (Present address, United States Naval Hospital, Philadelphia.)

‡ Resident in medicine, New England Deaconess Hospital.

§ Assistant clinical professor of medicine, Harvard Medical School; physician, New England Deaconess Hospital; physician, Joslin Clinic.

Print Subscriber? Activate your online access.